T-3262 in urogenital infection

We studied the utility of T-3262, a new quinolone antibacterial drug, by examining its transfer into human prostatic fluid (PF) and evaluating the clinical results 75 patients with urogenital infections. 1) Transfer into PF Concentrations of T-3262 1 hr after a 150 mg administration were 0.027±0.007 μg/ml (n=3) in PF and 0.265±0.004 μg/ml (n=3) in serum. 2) Results of clinical application (a) Urinary tract infection (UTI). 1) Simple acute cystitis : Patients were given 75 mg×2, 75 mg×3, 150 mg×2 or 150 mg×3 daily mostly for 3 days. The treatment was found to be markedly effective in 18 cases and effective in 5 of 23 cases assessed by the Japanese UTI Committee's criteria, thus proving it effective in 100% and markedly effective in 73.3% of the cases. 2) Chronic complicated diseases: Patients were given 75 mg×2, 75 mg×3, 150 mg×2, 150 mg×3 or 300 mg×2 daily mostly for 5 days. The treatment was markedly effective in 10 cases, effective in 8 and not effective in 11 of 29 cases which satisfied the criteria of the Japanese UTI Committee, a response rate of 62.1%. Therapeutic efficacy was examined according to the type of infection, and the drug proved effective in 7 (77.8%) of 9 patients with monomicrobial infection and 11 (55.0%) of 20 patients with polymicrobial infection. Twenty-six strains (92.9%) of 28 GPC isolates were eliminated by the treatment. (b) Urogenital infections : Of 3 patients with urethritis, treatment was ineffective in 2 with nongonorrheal urethritis, and markedly effective in 1 with gonorrheal urethritis. The treatment was effective in 3 (50%) of 6 cases of prostatitis which met the criteria. 3) Safety of the drug Side effects such as a heavy feeling in the head, urticaria, diarrhea and eruption were noted in 3 patients, an incidence of 4.0%.